There hasn't been any quarterly to date where the results exceeded the expectations - and many of the expectations have been fairly low.
Highest quarterly income was $124k in the last quarter - which mostly was the advanced payment from Janssen.
The biggest red flag to me and the main reason I sold out after years of holding, was the fact the BOD (especially TK) never able articulate how much money/profit they expect the make from each product. No forecast, no baseline, nothing.
In most of the major deals/announcements they almost always leave out any financial guidance on how much RAP would receive and their favourite line to use is:
"ResApp does not expect to generatematerial revenue from the initiative."
IMO TK and BOD have really sold out many loyal SHs.
Also can't wait how a certain oblivious poster going to spin this, who has been blindly defending TK/BOD over the years despite the downfall.
Rant over.
GLTAH and DYOR
Ann: Proposed Acquisition of ResApp Health by Pfizer, page-91
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #